Skip to content

5th German-speaking CytoSorb user meeting

Share on facebook
Share on twitter
Share on linkedin

On the eve of the 18th DIVI 2018 in Leipzig, CytoSorbents invited to the 5th German-speaking CytoSorb user meeting.

An excellent panel of speakers presented new data and insights in Leipzig on the following topics:

  • Sepsis and systemic hyperinflammation with interim evaluation of the CytoSorb registry
  • Practical aspects of CytoSorb therapy such as the beginning, end and time of the adsorber change
  • Use of CytoSorb in ECMO patients
  • Use of CytoSorb in severe burns
  • Other indications such as liver failure and rhabdomyolysis

More than 100 interested participants were present in Leipzig and there was a lively exchange of experience on the various fields of application of CytoSorb therapy. In addition to the interesting presentations, it became clear above all in the panel discussion that the discussions on the use of CytoSorb in the area of ​​systemic hyperinflammation have meanwhile achieved a new quality and, on the contrary, focus solely on specific questions regarding the dosing and timing of the therapy. The individual presentations will be available in a separate webcast below.

Due to the now well-established data and knowledge situation and the associated lectures on CytoSorb therapy in the intensive medical context, it has been decided to treat the CytoSorb therapy in cardiac surgery in an own user meeting. This 1st cardiac surgery CytoSorb user meeting will be held for the first time on 16 February 2019 in the run-up to the DGTHG conference in Wiesbaden.

So far, more than 51,000 individual applications have been performed in more than 800 clinical departments worldwide with CytoSorb therapy.

Gallery

Webcast

Video Playlist
1/5 Videos
1
01 Praktische Aspekte und neue Erfahrungen im Bereich Sepsis und systemische Hyperinflammation
01 Praktische Aspekte und neue Erfahrungen im Bereich Sepsis und systemische Hyperinflammation
2
02 Praktische Aspekte und neue Erfahrungen im Bereich Sepsis und systemische Hyperinflammation
02 Praktische Aspekte und neue Erfahrungen im Bereich Sepsis und systemische Hyperinflammation
3
03 Praktische Aspekte und neue Erfahrungen im Bereich Rhabdomyolyse
03 Praktische Aspekte und neue Erfahrungen im Bereich Rhabdomyolyse
4
04 Praktische Aspekte und neue Erfahrungen im Bereich Leberversagen
04 Praktische Aspekte und neue Erfahrungen im Bereich Leberversagen
5
Dr. Christian Steiner, CytoSorbents | 2018 | Leipzig
Dr. Christian Steiner, CytoSorbents | 2018 | Leipzig

About us

Cytosorbents Europe GmbH, headquartered in Berlin, is a wholly owned subsidiary of CytoSorbents Corporation of Monmouth Junction, New Jersey, USA, where the CytoSorb product is manufactured. CytoSorb is the company’s flagship product, backed by more than 30 patent families.

more events

Follow us

Subscribe to our newsletter now!

Get access to the CytoSorbents Community Area. The current newsletter contains a direct link to the CytoSorbents Community Area.